Clinical trial / 2016
Adding extended-release niacin with laropiprant to statin therapy reduced quality-adjusted life years and increased hospital costs over 4 years.
In the HPS2-THRIVE trial, 25,673 participants aged 50 to 80 years with prior cardiovascular disease receiving statin therapy were randomized to 2 g extended-release niacin with 40 mg laropiprant daily or placebo for 4 years. Participants assigned to niacin-laropiprant experienced non-significantly lower survival (0.012 fewer years [SE 0.007]), significantly fewer quality-adjusted life years (0.023 [SE 0.007] fewer using UK EQ-5D; 0.020 [SE 0.006] fewer using US EQ-5D), and higher hospital costs (UK £101 [SE £37]; US $145 [SE $53]). Stroke, heart failure, musculoskeletal, gastrointestinal, and infection events were associated with substantial declines in quality of life and increased hospital costs.
- Study type
- Randomized controlled trial
- Who was studied
- 25,673 participants aged 50 to 80 years with previous cardiovascular disease
- What was measured
- Quality-adjusted life years, survival, and hospital care costs
THE PAPER
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
Kent S, Haynes R, Hopewell JC, Parish S, Gray A, Landray MJ, Collins R, Armitage J, Mihaylova B, HPS2-THRIVE Collaborative Group. Circ Cardiovasc Qual Outcomes, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.